Pharma BD Deal Intelligence
Gilead/Kite's $567M bet on Cell Design Labs' synNotch and Throttle platforms never delivered a Gilead-branded oncology product—nearly eight years later, the acquired IP's biggest event was being licensed out to Kyverna Therapeutics for autoimmune disease, not built internally as intended.
The $567M synNotch/Throttle bet never produced a Gilead/Kite drug — the platform's biggest post-close event was being licensed OUT to a third-party spinout for autoimmune disease, not used internally for oncology as intended.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead deepens its CAR-T push with the $567M Cell Design Labs deal, securing UCSF-derived synthetic biology platforms (synNotch, Throttle) for next-generation…
UCSF spinout Cell Design Labs, founded on Wendell Lim's synNotch and Throttle technologies, is acquired by Gilead/Kite for up to $567M — validating UCSF's…
Gilead goes full throttle on CAR-Ts with the $567M Cell Design Labs acquisition, signaling intent to extend beyond Yescarta into tunable and logic-gated cell…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Gilead/Kite agreed to acquire Cell Design Labs, a UCSF spinout developing synthetic biology platforms (synNotch and Throttle) for next-generation engineered cell therapies. Total deal value up to $567M, including $175M for the ~87.6% Cell Design Labs equity Kite did not already own plus up to $322M in development milestones (~$567M aggregate). The deal expanded Kite's CAR-T platform technology toolkit.
The $567M synNotch/Throttle bet never produced a Gilead/Kite drug — the platform's biggest post-close event was being licensed OUT to a third-party spinout for autoimmune disease, not used internally for oncology as intended.
Assessment window: 5yr post-close.
First-generation CD19 CAR-T therapies (Yescarta, Kymriah) demonstrated durable remissions in B-cell malignancies but face limitations including on-target/off-tumor toxicity, antigen escape, T-cell exhaustion, and inability to address solid tumors. Next-generation engineered T-cell platforms aim to deliver tighter tumor specificity and conditional activation to expand into solid tumors and improve safety.
By December 2017, the cell therapy landscape was rapidly consolidating around big-pharma platforms following Gilead's $11.9B Kite acquisition (October 2017) and Celgene's $9B Juno acquisition (announced January 2018). Yescarta (axicabtagene ciloleucel) had been approved in October 2017 for relapsed/refractory large B-cell lymphoma; Novartis' Kymriah (tisagenlecleucel) was approved August 2017 for B-ALL. Next-generation platform competition included Celgene/Juno's defined-composition CAR-Ts, bluebird bio's bb2121 (BCMA), Allogene's allogeneic 'off-the-shelf' CAR-Ts (founded 2018 by ex-Kite leadership), and academic platforms from MSKCC, Penn, and UCSF. Cell Design Labs' synNotch and Throttle platforms — invented in the Wendell Lim lab at UCSF — offered conditional/dual-antigen activation logic addressing solid tumor specificity, a key differentiator versus single-antigen CD19 CAR-T constructs. BioPharma Dive characterized the deal as Gilead 'deepening its CAR-T push' and securing platform optionality. pharmaphorum noted Gilead going 'full throttle on CAR-Ts' to extend beyond Yescarta into next-gen logic-gated and tunable cell therapies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Cell Design Labs, Inc. (this deal) | 2017 | $567M | 21 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2017 deals · Gilead Sciences Inc. deals · Oncology deals